Oculis Holding AG (Oculis Holding AG) Days Payable : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Days Payable?

Oculis Holding AG's average Accounts Payable for the three months ended in Mar. 2024 was $5.05 Mil. Oculis Holding AG's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil.

The historical rank and industry rank for Oculis Holding AG's Days Payable or its related term are showing as below:

OCS's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

Oculis Holding AG's Days Payable stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00). stayed the same

Oculis Holding AG Days Payable Historical Data

The historical data trend for Oculis Holding AG's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Days Payable Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Days Payable

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Payable	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Oculis Holding AG's Days Payable

For the Biotechnology subindustry, Oculis Holding AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oculis Holding AG's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oculis Holding AG's Days Payable distribution charts can be found below:

* The bar in red indicates where Oculis Holding AG's Days Payable falls into.

Oculis Holding AG Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Oculis Holding AG's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (4.151	+	8.784)	/	2 )	/	0	*	365
=	6.4675					/	0	*	365
=	N/A

Oculis Holding AG's Days Payable for the quarter that ended in Mar. 2024 is calculated as:

	Days Payable (Q: Mar. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2023 )	+	Accounts Payable (Q: Mar. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2024 )	*	Days in Period
=	( (8.784	+	1.321)	/	2 )	/	0	*	365 / 4
=	5.0525					/	0	*	365 / 4
=	N/A

Oculis Holding AG Days Payable Related Terms

Thank you for viewing the detailed overview of Oculis Holding AG's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Oculis Holding AG (Oculis Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

OCS:Iceland

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.